Methyldopa and propranolol or practolol in moderate hypertension. 1976

J C Petrie, and D B Galloway, and T A Jeffers, and H R Millar, and M C Smith, and R A Wood, and J A Lewis, and W T Simpson

The effect of a low dose of methyldopa combined with (a) a non-selective and (b) a selective beta-adrenoceptor antagonist was studied in a double-blind crossover trial in 24 carefully selected patients with moderate hypertension (mean initial lying blood pressure 189/117 mm Hg). Each patient received methyldopa 750 mg/day, propranolol 240 mg/day, practolol 600 mg/day, methyldopa 750 mg/day combined with propranolol 240 mg/day, methyldopa 750 mg/day combined with practolol 600 mg/day, and placebo for four weeks each according to a random sequence. After four weeks of therapy the most effective treatment, methyldopa combined with propranolol, reduced lying and standing blood pressures by 36-5/21-4 mm Hg and 44-7/25 mm Hg respectively. Thic combination had similar effects to those of the combination of methyldopa with the cardioselective agent practolol except that it reduced lying diastolic pressure further. The combination was more effective than either treatment alone. No significant differences were found between the effects of propranolol, practolol, or methyldopa at the doses used.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011187 Posture The position or physical attitude of the body. Postures
D011217 Practolol A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS. Dalzic,Eralzdin Practolol,ICI-50172,ICI 50172,ICI50172,Practolol, Eralzdin
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D011674 Pulse The rhythmical expansion and contraction of an ARTERY produced by waves of pressure caused by the ejection of BLOOD from the left ventricle of the HEART as it contracts. Pulses
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic

Related Publications

J C Petrie, and D B Galloway, and T A Jeffers, and H R Millar, and M C Smith, and R A Wood, and J A Lewis, and W T Simpson
January 1980, Indian heart journal,
J C Petrie, and D B Galloway, and T A Jeffers, and H R Millar, and M C Smith, and R A Wood, and J A Lewis, and W T Simpson
January 1976, Advances in clinical pharmacology,
J C Petrie, and D B Galloway, and T A Jeffers, and H R Millar, and M C Smith, and R A Wood, and J A Lewis, and W T Simpson
August 1975, Current therapeutic research, clinical and experimental,
J C Petrie, and D B Galloway, and T A Jeffers, and H R Millar, and M C Smith, and R A Wood, and J A Lewis, and W T Simpson
July 1981, Postgraduate medical journal,
J C Petrie, and D B Galloway, and T A Jeffers, and H R Millar, and M C Smith, and R A Wood, and J A Lewis, and W T Simpson
November 1974, Current therapeutic research, clinical and experimental,
J C Petrie, and D B Galloway, and T A Jeffers, and H R Millar, and M C Smith, and R A Wood, and J A Lewis, and W T Simpson
March 1978, British journal of clinical pharmacology,
J C Petrie, and D B Galloway, and T A Jeffers, and H R Millar, and M C Smith, and R A Wood, and J A Lewis, and W T Simpson
September 1984, The Journal of the Association of Physicians of India,
J C Petrie, and D B Galloway, and T A Jeffers, and H R Millar, and M C Smith, and R A Wood, and J A Lewis, and W T Simpson
November 1973, Arzneimittel-Forschung,
J C Petrie, and D B Galloway, and T A Jeffers, and H R Millar, and M C Smith, and R A Wood, and J A Lewis, and W T Simpson
January 1971, Ugeskrift for laeger,
J C Petrie, and D B Galloway, and T A Jeffers, and H R Millar, and M C Smith, and R A Wood, and J A Lewis, and W T Simpson
January 1982, Pharmacotherapy,
Copied contents to your clipboard!